XML 125 R73.htm IDEA: XBRL DOCUMENT v3.25.4
Segment Information - Schedule of Financial Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Segment Reporting Information [Line Items]      
Revenue $ 262.6 $ 263.4 $ 78.5
Less:      
Total research and development expense 285.2 348.2 379.7
General and administrative expense 95.9 165.4 100.3
Income tax expense 0.3 0.6 0.9
Loss from equity method investment 0.0 0.0 2.5
Interest income, net 38.4 54.8 38.8
Segment net loss (80.8) (198.9) (367.3)
Reportable Segment      
Segment Reporting Information [Line Items]      
Revenue 262.6 263.4 78.5
Less:      
Non program-specific external expense 49.1 62.8 72.4
Compensation and related personnel expense (including stock-based compensation) 109.6 145.4 134.2
Other research and development expense 11.0 12.8 13.8
Total research and development expense 285.2 348.2 379.7
General and administrative expense 95.9 165.4 100.3
Other segment expense, net 0.4 2.9 1.2
Income tax expense 0.3 0.6 0.9
Loss from equity method investment 0.0 0.0 2.5
Interest income, net 38.4 54.8 38.8
Segment net loss (80.8) (198.9) (367.3)
Reportable Segment | Vepdegestrant ARV-471      
Less:      
Program-specific external expense: 62.7 76.9 104.8
Reportable Segment | ARV-102      
Less:      
Program-specific external expense: 21.0 13.0 2.3
Reportable Segment | ARV-806      
Less:      
Program-specific external expense: 13.5 2.3 0.0
Reportable Segment | ARV-393      
Less:      
Program-specific external expense: 11.1 6.8 1.4
Reportable Segment | Bavdegalutamide (ARV-110)      
Less:      
Program-specific external expense: 2.7 8.5 26.6
Reportable Segment | Luxdegalutamide (ARV-766)      
Less:      
Program-specific external expense: 0.0 19.7 24.2
Reportable Segment | Other programs      
Less:      
Program-specific external expense: $ 4.5 $ 0.0 $ 0.0